Muhammad Kaleem, MD
Pulmonary Disease · Gadsden, ALNPI 1285697078
Payments from drug & device makers
Across 246 payments — averaging $20.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$927
- AstraZeneca$639
- Intuitive Surgical$527
- Sanofi$427
- Insmed, Inc.$365
- Harmony Biosciences LLC$338
- plus $2K from 20 others
What the payments were for
- Travel & lodging$3006%
- Food & beverage$4,34387%
- Education$3527%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 65 | $927 |
| AstraZeneca | 34 | $639 |
| Intuitive Surgical | 8 | $527 |
| Sanofi | 18 | $427 |
| Insmed, Inc. | 18 | $365 |
| Harmony Biosciences LLC | 9 | $338 |
| Boehringer Ingelheim | 16 | $328 |
| Regeneron Healthcare Solutions, Inc. | 9 | $246 |
| Genentech USA, Inc. | 11 | $186 |
| Amgen | 8 | $169 |
| Grifols USA, LLC | 10 | $162 |
| Electromed, Inc. | 9 | $126 |
| Philips North America LLC | 7 | $125 |
| Pfizer | 6 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $71 |
| Mylan Specialty L.p. | 3 | $57 |
| CSL Behring | 2 | $39 |
| Vifor Pharma, Inc. | 1 | $34 |
| Verona Pharma, Inc. | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Merck | 2 | $25 |
| United Therapeutics Corporation | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Melinta Therapeutics, LLC | 1 | $16 |
| Johnson & Johnson | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,995 in reported general payments places this provider in the 55th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 39 | $508,812 |
| OfevNintedanib Esylate | 36 | $468,827 |
| TezspireTezepelumab-Ekko | 70 | $289,859 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 359 | $263,217 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 67 | $50,031 |
| EliquisApixaban | 44 | $25,200 |
| Spiriva RespimatTiotropium Bromide | 29 | $20,686 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $17,102 |
| FarxigaDapagliflozin Propanediol | 18 | $10,207 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $6,764 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 194 | $6,056 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $5,595 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,519 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $4,392 |
| Roflumilast | 39 | $4,273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCProlastin C | $162 | $508,81239 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $328 | $495,03177 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Farxiga | $639 | $350,098155 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $927 | $287,084410 claims |
| PfizerEliquis | $76 | $25,20044 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Gadsden
- Kumadchand ShahGadsden$96K
- Robert GarverAndalusia$4.6M
- Allan SeibertMobile$2.4M
- Tejaswini KulkarniBirmingham$1.7M
- Jan WestermanJasper$834K
- Bryan GarciaBirmingham$606K
- A RidgewaySheffield$434K
- Darryle BullardCullman$380K
- Marvin SextonDothan$346K
- Veena AntonyBirmingham$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.